September 30, 2019 – Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults “Systemic events (defined as fatigue, headache, chills, nausea/ vomiting, new muscle pain, aggravated muscle pain, new joint pain, and aggravated joint pain) were reported by a higher proportion of subjects in the PCV20 group (72.7%) compared to the Tdap group (57.6%) The
